Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated

Latest Fibroblast Growth Factor 21 Articles

Fibroblast Growth Factor 21 Archives
Print | Email | Share | Comments (0)

Promising New Type 2 Drug on Horizon


Nov 16, 2013

A new drug being developed by Eli Lilly Co. that duplicates the effects of a hormone may soon be added to the growing arsenal of pharmaceutical weapons available to treat type 2 diabetes.

The injectable drug, called LY, is designed to mimic the effects of the hormone fibroblast growth factor 21 (FGF21), which is produced by the liver and helps regulate the metabolism of both blood glucose and blood fat (lipids).

Over the course of a month-long trial, 46 patients with type 2 diabetes were injected either with daily doses of the drug at various levels or a placebo. Those who received the highest doses of the drug saw significant improvements in blood fat and cholesterol levels compared to those who received the placebo.

Insulin and blood sugar levels, however, were not significantly impacted, though patients on the higher doses of the drug also lost some weight, researchers said.

"Our current understanding suggests that FGF21 has the ability to favorably affect body weight, partially normalize abnormal lipid levels in patients with diabetes, and has the potential to improve glycemic control," said senior study author Dr. Dave Moller, vice president of endocrinology and cardiovascular research, and clinical investigation for Eli Lilly.

The trial did show the potential for some side effects from the injectable hormone, including allergic reactions as well as immune responses that could cause the drug to lose effectiveness over time.

The study appeared in a September 2013 issue of the journal Cell Metabolism.

 


Categories: Eli Lilly, FGF21, Fibroblast Growth Factor 21, LY



You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 0 comments - Nov 16, 2013

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.